Carlsmed (NASDAQ:CARL) outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential drivers of growth during a Bank of America small- and mid-cap virtual event. Chief Executive Officer Mik

Strong surgeon adoption and favorable CMS reimbursement ruling drive growth, though net losses widen amid increased investment.

Carlsmed (NASDAQ:CARL) reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical offering lifted procedure volumes. Chairman and Chief Executive Officer Mike Cordonnier said the

Carlsmed, Inc. (CARL) delivered earnings and revenue surprises of +2.50% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -26.09% and -9.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Carlsmed, Inc. (CARL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.